{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:55:28Z","timestamp":1766516128278,"version":"build-2065373602"},"reference-count":36,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T00:00:00Z","timestamp":1742601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017415","name":"Peking University First Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017415","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.urolonc.2025.03.016","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T23:54:41Z","timestamp":1745452481000},"page":"443.e11-443.e19","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enhancing outcomes in metastatic renal cell carcinoma: Integrating precision radiotherapy with targeted therapy and anti-PD-1 immunotherapy"],"prefix":"10.1016","volume":"43","author":[{"given":"Ming-Wei","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Wei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xian-Shu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Song","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Yan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2025.03.016_bib0001","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.euo.2023.01.010","article-title":"Survival by depth of response and efficacy by international metastatic renal cell carcinoma database consortium subgroup with lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinoma: analysis of the phase 3 randomized CLEAR study","volume":"6","author":"Gr\u00fcnwald","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0002","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S1470-2045(23)00049-9","article-title":"Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR) : extended follow-up from the phase 3, randomised, open-label study","volume":"24","author":"Choueiri","year":"2023","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0003","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(23)00276-0","article-title":"Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial","volume":"24","author":"Albiges","year":"2023","journal-title":"Lancet Oncol"},{"unstructured":"NCCN clinical practice guidelines in oncology: kidney cancer (2024 Version1).https:\/\/www.nccn.org\/profile?ReturnURL=https%3a%2f%2fwww.nccn.org%2fprofessionals%2fphysician_gls%2fpdf%2fkidney.pdf","key":"10.1016\/j.urolonc.2025.03.016_bib0004"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2025.102881","article-title":"Dynamics of resistance to immunotherapy and TKI in patients with advanced renal cell carcinoma","volume":"133","author":"Santoni","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0006","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1200\/JCO.20.00818","article-title":"Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial","volume":"38","author":"Palma","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0007","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.eururo.2022.06.017","article-title":"The role of stereotactic ablative body radiotherapy in renal cell carcinoma","volume":"82","author":"Ali","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0008","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.eururo.2021.12.006","article-title":"Stereotactic radiotherapy and short-course pembrolizumab for oligometastatic renal cell carcinoma-the RAPPORT trial","volume":"81","author":"Siva","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0009","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.eururo.2021.09.016","article-title":"Nivolumab in combination with stereotactic body radiotherapy in pretreated patients with metastatic renal cell carcinoma. Results of the phase II NIVES study","volume":"81","author":"Masini","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0010","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.2147\/OTT.S159538","article-title":"Partial stereotactic ablative boost radiotherapy in bulky non-small cell lung cancer: a retrospective study","volume":"11","author":"Bai","year":"2018","journal-title":"Onco Targets Ther"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0011","doi-asserted-by":"crossref","first-page":"7832","DOI":"10.3390\/curroncol29100619","article-title":"Outcomes of high-dose stereotactic ablative radiotherapy to all\/multiple sites for oligometastatic renal cell cancer patients","volume":"29","author":"Ma","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0012","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.15514","article-title":"Partial stereotactic ablative radiotherapy boost before conventional radiotherapy (P-SABR) for large (>\u20095\u2009cm) unresectable stage III nonsmall cell lung cancer","volume":"16","author":"Bai","year":"2025","journal-title":"Thorac Cancer"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0013","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM task group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0014","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0015","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0016","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11060-004-1718-y","article-title":"PKB\/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas","volume":"71","author":"Nakamura","year":"2005","journal-title":"J Neuro-oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0017","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1756-8722-3-8","article-title":"From basic research to clinical development of MEK1\/2 inhibitors for cancer therapy","volume":"3","author":"Fremin","year":"2010","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0018","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1038\/sj.onc.1208715","article-title":"Enhanced radiation damage of tumor vasculature by mTOR inhibitors","volume":"24","author":"Shinohara","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/s41571-018-0119-7","article-title":"Time to abandon single-site irradiation for inducing abscopal effects","volume":"16","author":"Brooks","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.radonc.2021.01.001","article-title":"Incidence, risk factors, and CT characteristics of radiation recall pneumonitis induced by immune checkpoint inhibitor in lung cancer","volume":"157","author":"Cousin","year":"2021","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0021","article-title":"Crossed pathways for radiation-induced and immunotherapy-related lung injury","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0022","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/S1470-2045(20)30436-8","article-title":"Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0023","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13014-021-01937-9","article-title":"Stereotactic body radiotherapy in combination with non-frontline PD-1 inhibitors and targeted agents in metastatic renal cell carcinoma","volume":"16","author":"Liu","year":"2021","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0024","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0025","article-title":"Comprehensive pneumonitis profile of thoracic radiotherapy followed by immune checkpoint inhibitor and risk factors for radiation recall pneumonitis in lung cancer","volume":"13","author":"Lu","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0026","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamaoncol.2021.6439","article-title":"Association of radiation therapy with risk of adverse events in patients receiving immunotherapy: a pooled analysis of trials in the US food and drug administration database","volume":"8","author":"Anscher","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0027","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s12094-022-02793-z","article-title":"The role of stereotactic body radiotherapy in switching systemic therapy for patients with extracranial oligometastatic renal cell carcinoma","volume":"24","author":"Onal","year":"2022","journal-title":"Clin Translat Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0028","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/COC.0000000000000622","article-title":"Survival outcomes after adding stereotactic body radiotherapy to metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors","volume":"43","author":"He","year":"2020","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1095775","article-title":"Genomic profiles of renal cell carcinoma in a small Chinese cohort","volume":"13","author":"Tai","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0030","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.juro.2008.05.015","article-title":"von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma","volume":"180","author":"Choueiri","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0031","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000230","article-title":"DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy","volume":"8","author":"Ged","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0032","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/1078-0432.CCR-18-1833","article-title":"PTEN expression, not mutation status in TSC1, TSC2, or mTOR, correlates with the outcome on Everolimus in patients with renal cell carcinoma treated on the randomized RECORD-3 trial","volume":"25","author":"Voss","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0033","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.euo.2022.11.006","article-title":"Genomic and transcriptomic predictors of response from stereotactic body radiation therapy in patients with oligoprogressive renal cell carcinoma","volume":"6","author":"Zengin","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0034","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0035","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/cancers16101835","article-title":"Prognostic significance of the Royal Marsden Hospital (RMH) Score in patients with cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.urolonc.2025.03.016_bib0036","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.euo.2023.07.003","article-title":"Real-world outcome of patients with advanced renal cell carcinoma and intermediate- or poor-risk international metastatic renal cell carcinoma database Consortium criteria treated by immune-oncology combinations: differential effectiveness by risk group?","volume":"7","author":"Santoni","year":"2024","journal-title":"Eur Urol Oncol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001206?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143925001206?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T17:32:08Z","timestamp":1762363928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143925001206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1078143925001206"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.016","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing outcomes in metastatic renal cell carcinoma: Integrating precision radiotherapy with targeted therapy and anti-PD-1 immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2025.03.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}